Revenue FY2025
$24.0M
Net Income
$(243.0M)
EPS (Basic)
$-2.86
Net Margin
-1011.7%
ROE
-80.8%
Total Equity
$301.0M
Shares Out
—
ALUMIS INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2023–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 4 funds in our universe
Insider Transactions
Reading stored insider transactions…